Molecular markers in prostate cancer. Part II: potential roles in management

被引：4

作者：

Agrawal, Sachin ^{[1
]}

Patil, Krishnaji P. ^{[1
]}

Dunsmuir, William D. ^{[1
]}

机构：

[1] St Peters Hosp, Dept Urol, Chertsey KT16 0PZ, England

来源：

ASIAN JOURNAL OF ANDROLOGY | 2009年 / 11卷 / 01期

关键词：

genetics; management; molecular; prostate cancer; GROWTH-FACTOR RECEPTOR; SUICIDE GENE-THERAPY; PHASE-I; C-MYC; BONE METASTASIS; CLINICAL-TRIAL; EXPRESSION; CELLS; CARCINOMA; ANTIGEN;

D O I：

10.1038/aja.2008.23

中图分类号：

R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

摘要：

Predicting treatment responses in advanced prostate cancer (PCa) currently centres on prostate-specific antigen (PSA) kinetics and on being able to visualize measurable changes in imaging modalities. New molecular markers have emerged as potential diagnostic and prognostic indicators; these were summarized in Part I of this review in the Asian Journal of Andrology. A number of molecular markers are now being used to enhance PCa imaging and staging. However, management options for advanced and hormone-resistant PCa (HRPC) are limited and additional therapeutic options are needed. Molecular markers have been proposed as potential therapeutic targets using gene therapy and immunomodulation. Additionally, markers identified in early PCa and precursor lesions may offer novel targets for chemoprevention and vaccine development. This review summarizes the current advances regarding the roles of these markers in the management of PCa.

引用

页码：22 / 27

页数：6

共 51 条

[21]

Golias Ch., 2007, Experimental Oncology, V29, P82

[22] Chemoprevention using dutasteride: the REDUCE trial [J].

Gomella, LG .

CURRENT OPINION IN UROLOGY, 2005, 15 (01) :29-32

[23] Genetic changes and DNA damage responses in the prostate [J].

Hallstrom, Taija M. Kiviharju-af ;

Laiho, Marikki .

PROSTATE, 2008, 68 (08) :902-918

[24] In situ gene therapy for adenocarcinoma of the prostate:: A phase I clinical trial [J].

Herman, JR ;

Adler, HL ;

Aguilar-Cordova, E ;

Rojas-Martinez, A ;

Woo, S ;

Timme, TL ;

Wheeler, TM ;

Thompson, TC ;

Scardino, PT .

HUMAN GENE THERAPY, 1999, 10 (07) :1239-1249

[25]

HOROSZEWICZ JS, 1987, ANTICANCER RES, V7, P927

[26]

HUSSAIN A, 2008, UPTODATE

[27] Focus on prostate cancer [J].

Isaacs, W ;

De Marzo, A ;

Nelson, WG .

CANCER CELL, 2002, 2 (02) :113-116

[28] Stem cells in prostate cancer initiation and progression [J].

Lawson, Devon A. ;

Witte, Owen N. .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (08) :2044-2050

[29] Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells [J].

Lin, Amy M. ;

Hershberg, Robert M. ;

Small, Eric J. .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (05) :434-441

[30] Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity [J].

Lipinski, KS ;

Pelech, S ;

Mountain, A ;

Irvine, AS ;

Kraaij, R ;

Bangma, CH ;

Mills, KHG ;

Todryk, SM .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (03) :347-354

← 1 2 3 4 5 6 →